The Kidney Interagency Coordinating Committee (KICC) will hold a meeting on September 25, 2015, on the pharmacist's role in chronic kidney disease care. The meeting is open to the public.
The meeting will be held on September 25, 2015, 9 a.m. to 12 p.m. Individuals wanting to present oral comments must notify the contact person at least 10 days before the meeting date.
The meeting will be held in the Natcher Conference Center on the NIH Campus at 9000 Rockville Pike, Bethesda, MD 20894.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
For further information concerning this meeting, contact Dr. Andrew S. Narva, Executive Secretary of the Kidney Interagency Coordinating Committee, National Institute of Diabetes and Digestive and Kidney Diseases, 31 Center Drive, Building 31A, Room 9A27, MSC 2560, Bethesda, MD 20892-2560, telephone: 301-594-8864; FAX: 301-480-0243; email: email@example.com.
End Further Info
Start Supplemental Information
The KICC, chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), comprises members of the Department of Health and Human Services and other federal agencies that support kidney-related activities, facilitates cooperation, communication, and collaboration on kidney disease among government entities. KICC meetings, held twice a year, provide an opportunity for Committee members to learn about and discuss current and future kidney programs in KICC member organizations and to identify opportunities for collaboration. The September 25, 2015 KICC meeting will focus on the pharmacist's role in chronic kidney disease care.
Any member of the public interested in presenting oral comments to the Committee should notify the contact person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives or organizations should submit a letter of intent, a brief description of the organization represented, and a written copy of their oral presentation in advance of the meeting. Only one representative of an organization will be allowed to present; oral comments and presentations will be limited to a maximum of 5 minutes. Printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the Committee by forwarding their statement to the contact person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Because of time constraints for the meeting, oral comments will be allowed on a first-come, first-serve basis.
Members of the public who would like to receive email notification about future KICC meetings should send a request to firstname.lastname@example.org.
End Supplemental Information
Dated: August 4, 2015.
Camille M. Hoover,
Executive Officer, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.
[FR Doc. 2015-20219 Filed 8-14-15; 8:45 am]
BILLING CODE 4140-01-P